Ibrance

Background

IBRANCEĀ® (palbociclib) is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women, fulvestrant in women with disease progression following endocrine therapy.

Therapeutic Area

HR+
HER2- adjuvant breast cancer

Acquisition Date

Jan 2016

Marketer

Seller